Cardio-protective effect of trimetazidine in patients with disseminated breast cancer

Abstract Funding Acknowledgements Type of funding sources: None. Relevance the problem. Anthracycline cardiotoxicity is most unfavorable form due to irreversible complications cardiovascular system caused by anthracyclines during chemotherapy (CT) breast cancer (BC). Despite fact that this type has been studied better than others, problem preventing such remains relevant day. In our study, we suggest Trimetadizine (TMZ) as a cardioprotective agent in patients with disseminated receiving Doxorubicin chemotherapy. Material and methods The study included 93 (aged 41.2±8.3 years) who underwent surgery for several courses (according stage cancer). Patients were randomized into 2 groups: first group (n=47; G1) received TMZ at dose 70 mg daily, control (n=46; G2) didn't receive TMZ. All before start complete echocardiographic examination checked cardiac biomarkers troponin brain natriuretic peptide (BNP). exclusion criterion was any kind pathology. primary endpoint reduction left ventricular ejection fraction (LVEF) deterioration assessed series studies conducted after each course chemotherapy, then every 3 months completion 1 year. Secondary outcome measures (EchoCG) measurements LV diastolic dysfunction, structural myocardial changes echocardiography, biomarkers. Results Both groups achieved same cumulative Doxorubicin. No patient died or discontinued study. There no significant differences between two terms baseline clinical findings, parameters, 3-5 CT, standard echocardiography showed unreliable LVEF, shortening fraction, measurements. However, tissue Doppler decrease velocity (P = 0.001) G2, indicating dysfunction. While observed G1. Conclusion Tissue proved be more sensitive early diagnosis appears have effect case anthracycline cardiotoxicity.